Gapping down:
Earnings/guidance: FINL -14.1%, SCS -9.5%, LNN -3.8%, ACN -3.3%, FDX -2.5%
Other news:
- XGTI -55.0% (prices approx. $10 mln offering of Class A and Class B Units, Class A Units were priced at $2.00)
- MACK -19.9% (stops the Phase 2 HERMIONE study of MM-302 in HER2-positive metastatic breast cancer patients who had previously been treated with trastuzumab, pertuzumab and ado-trastuzumab emtansine)
- AAAP -4.6% (FDA has issued a complete response letter regarding the NDA for Lutathera for the treatment of gastroenteropancreatic neuroendocrine tumors)
- SBGL -2.6% (still checking)
- FL -2.1% (FINL earnings read-through)
- DKS -1.2% (FINL earnings read-through)
- UPS -1.2% (FDX earnings read-through)
- TWTR -1.2% (CTO Adam Messinger to leave the company)
Analyst actions:
- NYCB -1.7% (downgraded at Raymond James, Morgan Stanley, FBR & Co following terminated merger with AF)